Abstract:Activation of the toll-like receptors 7 and 8 has emerged as a promising strategy for cancer immunotherapy. Herein, we report the design and synthesis of a series of pyrido[3,2-d]pyrimidine-based toll-like receptor 7/8 dual agonists that exhibited potent and near-equivalent agonistic activities toward TLR7 and TLR8. In vitro, compounds 24e and 25a significantly induced the secretion of IFN-α, IFN-γ, TNF-α, IL-1β, IL-12p40, and IP-10 in human peripheral blood mononuclear cell assays. In vivo, compounds 24e, 24m, and 25a significantly suppressed tumor growth in CT26 tumor-bearing mice by remodeling the tumor microenvironment. Additionally, compounds 24e, 24m, and 25a markedly improved the antitumor activity of PD-1/PD-L1 blockade. In particular, compound 24e combined with the anti-PD-L1 antibody led to complete tumor regression. These results demonstrated that TLR7/8 agonists (24e, 24m, and 25a) held great potential as single agents or in combination with PD-1/PD-L1 blockade for cancer immunotherapy.The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acs.jmedchem.1c00179?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.jmedchem.1c00179</a>.Homology and similarity analysis between TLR7 and 8; agonistic activities of compounds 24e, 25a, and 26a in other homologous TLRs; supplementary multiplexed immunoassays for cytokines; synergy analysis of tumor size and the survival rate; representative flow cytometric analysis of tumor-infiltrating immune cells; detection of absolute counts of tumor-infiltrating immune cells and synergy analysis; relationships between the TVs and the amounts of immune cells; phospholipidosis detection of 24e, 24m, and 25a; synthesis of compounds 16a, 27, and 35; NMR spectra of target compounds; and HPLC traces of compounds 5, 24e, 24k, 24m, 25a, and 34 (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.1c00179/suppl_file/jm1c00179_si_001.pdf">PDF</a>)Molecular formula strings (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.1c00179/suppl_file/jm1c00179_si_002.csv">CSV</a>)Molecular docking for GS-9620 into TLR7 and molecular docking for 17d, 24e, 24m, and 34, into TLR7 and TLR8 (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.1c00179/suppl_file/jm1c00179_si_003.zip">ZIP</a>)This article has not yet been cited by other publications.

Synthesis and Immunoregulatory Activities of Conjugates of a Toll-like Receptor 7 Inert Ligand

Toll-like receptor 7 inactive ligands enhanced cytokine induction by conjugation to weak antigens.

Synthesis and Evaluation of Conjugates of Novel TLR7 Inert Ligands As Self-Adjuvanting Immunopotentiators.

Conjugation of Weak Ligands with Weak Antigens to Activate TLR-7: A Step Toward Better Vaccine Adjuvants.

Conjugation of TLR7 and TLR7/8 agonists onto weak protein antigen via versatile oxime ligation for enhanced vaccine efficacy

Covalently Conjugated NOD2/TLR7 Agonists Are Potent and Versatile Immune Potentiators

Synthesis, evaluation and molecular dynamics study of human toll-like receptor 2/6 specific monoacyl lipopeptides as candidate immunostimulants

Molecule Engineering Strategy of Toll-Like Receptor 7/8 Agonists Designed for Potentiating Immune Stimuli Activation

Design and Optimization of Selectivity-Tunable Toll-like Receptor 7/8 Agonists as Novel Antibody-Drug Conjugate Payloads

Design, Synthesis, and Biological Evaluation of New 2,6,7-Substituted Purine Derivatives as Toll-like Receptor 7 Agonists for Intranasal Vaccine Adjuvants

Structure-Based Design of Highly Potent Toll-like Receptor 7/8 Dual Agonists for Cancer Immunotherapy

Design and Immunological Evaluation of a Hybrid Peptide As a Potent TLR2 Agonist by Structure-Based Virtual Screening.

Amino Acid-Dependent Attenuation Of Toll-Like Receptor Signaling By Peptide-Gold Nanoparticle Hybrids

Identification of novel and potent synthetic TLR agonists

The Development of a Highly Potent and Selective Human Toll-like Receptor 2 Agonist: Synthesis and Biological Evaluation of CaLGL-1 and Its Derivatives

Synergistic immune augmentation enabled by covalently conjugating TLR4 and NOD2 agonists

Design and Synthesis of Polyphenolic Imidazo[4,5- c]quinoline Derivatives to Modulate Toll Like Receptor-7 Agonistic Activity and Adjuvanticity

Conjugation of a Toll-Like Receptor Agonist to Glycans of an HIV Native-Like Envelope Trimer Preserves Neutralization Epitopes

Codelivery of Nod2 and Tlr9 Ligands Via Nanoengineered Protein Antigen Particles for Improving and Tuning Immune Responses

RNA-Based Immunostimulatory Liposomal Spherical Nucleic Acids As Potent TLR7/8 Modulators

Modulation Of Innate Immune Responses With Synthetic Lipid A Derivatives